The Pancreatic Cancer Drugs Market is segmented by Drug Type (Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other), Cancer Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), End-User (Hospitals, Clinics), and Region (North America, Europe, Asia-Pacific, and the Rest of the World).
What is pancreatic cancer?
Pancreatic cancer is defined as a kind of cancer that happens within the tissues of the pancreas. The pancreas is found behind the stomach and it aids in digestion by producing enzymes needed by the body to digest fats, proteins, and carbohydrates. Supported type, pancreatic cancer may be categorized as Abraxane (paclitaxel albumin-stabilized nanoparticle formulation), Afinitor (everolimus), erlotinib hydrochloride, everolimus, and 5-fu (fluorouracil injection) among others.
The market has been bifurcated into hospitals and clinics. The hospitals segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the presence of established infrastructure and skilled staff.
The North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the growing emphasis on the adoption of advanced diagnostic solutions in the healthcare industry coupled with the presence of key market players such as Eli Lilly and Company (US) and Celgene Corporation (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people suffering from pancreatic cancer.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to email@example.com.